SL-85. Tubulin Inhibitors

ASINEX
Signature Libraries

Microtubule interfering agents that disrupt microtubule/tubulin dynamics are widely used in anti-cancer therapy [1]. Currently several highly efficacious tubulin inhibitors targeting the taxane (e.g. Paclitaxel) and the vinca (e.g. Vincristine) binding sites in tubulin are FDA approved. It is suggested that molecules targeting the colchicine binding site in tubulin could have an advantage over taxane and vinca binding molecules as they might be less susceptible to transporter medicated drug resistance.

A series of novel phenoxazine and phenothiazine derivatives have been recently reported as privileged chemotypes in the discovery and development of novel tubulin polymerization inhibitors [2]. Computational studies suggested that these compounds bind to β-tubulin at the colchicine binding site.

Structural analogs of the reported hit series were included into this library.



ASN 10027188



BAS 03049926



ASN 10358262



33b [2]



15g [3]



16o [3]

Signature Library 85

Formats	Supplementary Information
80 compounds per plate 0.1 mg; 1 mg; 2 mg dry film/powder 0.1 µmol; 1 µmol DMSO solutions	SL#85_tubulin_inh.sdf

References:

1. *Expert Opin Investig Drugs. 2016 Aug;25(8):917-36.* doi: 10.1080/13543784.2016.1189901
2. *J. Med. Chem., 2011, 54 (12), pp 4247–4263*. doi: 10.1021/jm200436t
3. J. Med. Chem., 2017, 60 (2), pp 749–766. doi: 10.1021/acs.jmedchem.6b01591

Contact us:

USA:	+1 336 721 1617	asinex@asinex.com
Japan:	+81-80-3401-9097	sota@asinex.com
Europe/Global:		lsadovenko@asinex.com

ASINEX
Signature Libraries

asinex.com